| Date | Title | Description |
| 01.08.2025 | The Oligonucleotide Therapeutics Society Announces the 21st Annual Meeting in Budapest, Hungary | Share
Share
Share
Share
Email
The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October 19–22, 2025, at the Budapest Congress Center in Budapest, Hungary.
This premier global ga... |
| 10.07.2024 | BOLDEN THERAPEUTICS TO PRESENT AT THE 4TH ANNUAL OLIGONUCLEOTIDES FOR CNS SUMMIT | PROVIDENCE, R.I., July 10, 2024 /PRNewswire/ -- Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of CNS illnesses, today announced their invitation... |
| 13.06.2024 | The Lustgarten Foundation Appoints Two New Board Members | To date, the foundation has invested more than $282M in high-risk, high-reward research to accelerate and expand life-saving treatment options.
Richard Barakat, MD, and Aaron Kantoff join the Lustgarten Foundation Board of Directors
WOODBUR... |
| 07.04.2022 | Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting | New preclinical data support the ongoing preclinical development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA) |
| 07.04.2022 | Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting | New preclinical data support the ongoing preclinical development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA)
ADOA is the most common inherited optic nerve disorder
BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 7, 2022-... |
| 10.03.2022 | Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates | – Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children and adolescents with Dravet syndrome –
– Company remains on track to provide additional clinical data in 2H 2022 from patients treated wit... |
| 10.03.2022 | Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates | – Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children and adolescents with Dravet syndrome – |
| 03.12.2021 | Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting | Single doses of STK-001 up to 30mg and multiple doses of 20mg were well tolerated with no safety concerns related to study drug |
| 03.12.2021 | Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting | Single doses of STK-001 up to 30mg and multiple doses of 20mg were well tolerated with no safety concerns related to study drug
70.6% (12/17) of patients treated with STK-001 experienced a reduction from baseline in convulsive seizure freq... |
| 08.11.2021 | Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates - Form 8-K | Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
- Company nominates STK-002 as clinical candidate for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve d... |
| 21.09.2021 | Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome | – Results show that single doses of STK-001 up to 30mg and multiple doses of 20mg were well-tolerated with no safety concerns related to the study drug –
– A trend toward a reduction in convulsive seizure frequency was observed among patie... |
| 30.03.2021 | Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom | New ADMIRAL study complements ongoing U.S. studies and marks first step in global expansion of clinical development of STK-001 |
| 30.03.2021 | Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom | New ADMIRAL study complements ongoing U.S. studies and marks first step in global expansion of clinical development of STK-001
Study will evaluate safety and PK of multiple doses of STK-001 starting at 30mg; Enrollment and dosing anticipat... |
| 24.11.2020 | Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closi... |
| 06.08.2019 | Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome | BEDFORD, Mass. August 6, 2019 --(BUSINESS WIRE)-- Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today a... |
| 21.06.2019 | Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | BEDFORD, Ma, June 21, 2019 -- (BUSINESS WIRE) -- Stoke Therapeutics, Inc.(Nasdaq: STOK), a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, to... |
| 21.06.2019 | Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | BEDFORD, Ma, June 21, 2019 -- (BUSINESS WIRE) -- Stoke Therapeutics, Inc.(Nasdaq: STOK), a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, to... |
| 24.10.2018 | Term Sheet — Wednesday, October 24 | DEAD AND GONE
STARTUP GRAVEYARD: 2018 will forever be remembered as the year that blood testing startup Theranos took its last breath. But it wasn’t the only one. So far this year, a total of 12 companies have gone out of business, accordin... |
| 23.10.2018 | Stoke Therapeutics Scores $90M Series B |
BEDFORD, MA, Stoke Therapeutics today announced that it has completed a $90 million Series B financing.
>> Click here for more funding data on Stoke Therapeutics
>> To export Stoke Therapeutics funding data to PDF and Excel,... |
| 23.10.2018 | Stoke Therapeutics Raises $90M in Series B Financing | Stoke Therapeutics, a Bedford, Mass.-based biotechnology company, completed a $90m Series B financing.
The round was led by RTW Investments with participation from founding investor Apple Tree Partners and new investors RA Capital Managemen... |
| 23.10.2018 | Stoke Therapeutics Raises $90M In Series B | BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics today announced that it has completed a $90 million Series B financing to advance its pipeline of antisense oligonucleotide medicines for Dravet Syndrome and other severe genetic diseases.... |
| 23.10.2018 | Stoke Therapeutics Raises $90M In Series B | BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics today announced that it has completed a $90 million Series B financing to advance its pipeline of antisense oligonucleotide medicines for Dravet Syndrome and other severe genetic diseases.... |
| 04.01.2018 | Stoke Therapeutics Raises $40M in Series A Financing | Stoke Therapeutics, Inc., a Bedford, MA-based new company working to increase gene expression to treat a wide array of diseases caused by genetic insufficiency, completed a $40m Series A financing.
The round was provided by founding investo... |
| 04.01.2018 | Stoke Therapeutics Lands $40M |
BEDFORD, MA, Stoke Therapeutics Inc, which works to increase gene expression to treat diseases caused by genetic insufficiency, has raised $40 million in Series A financing.
>> Click here for more funding data on Stoke Therapeutics... |
| 04.01.2018 | Apple Tree Partners Leads $40M Series A for Stoke Therapeutics | BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc, a new company working to increase gene expression to treat a wide array of diseases caused by genetic insufficiency, today announced that it has completed a $40 million Series A fina... |
| 04.01.2018 | Stoke Therapeutics Raises $40M Series A | BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc, a new company working to increase gene expression to treat a wide array of diseases caused by genetic insufficiency, today announced that it has completed a $40 million Series A fina... |
